

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/000567

A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl⁷ C07K16/28, C12N15/09, C12Q1/02, A61K45/00, 37/02, 39/395,
A61P29/00, G01N33/15, 33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl⁷ C07K16/00-46, C12N15/00-90, C12Q1/00-70, A61K45/00, 37/02,
39/395, A61P29/00, G01N33/15, 33/50

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

JICST FILE (JOIS), EUROPAT (QUESTEL), MEDLINE/BIOSIS/WPIDS (STN),
SwissProt/PIR/GeneSeq, Genbank/EMBL/DDBJ/GeneSeq

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	C. Stumpf et al., Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure, 2003, Eur.J.Heart Fail, 5(5), p.629-37	1-5
A	S. Weng et al., β 3 integrin deficiency promotes atherosclerosis and pulmonary inflammation in high-fat-fed, hyperlipidemic mice, 2003, Proc. Natl.Acad.Sci.USA, 100(11), p.6730-5	1-19
A	C.S. Elangbam et al., Cell adhesion molecules—update, Veterinary Pathology, 1997, 34(1), pages 61 to 73	1-19
A	F.N. Lauw et al., Proinflammatory Effects of IL-10 During Human Endotoxemia, 2000, The Journal of Immunology, 165, p.2783-9.	1-19



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search
10 March, 2005 (10.03.05)

Date of mailing of the international search report
29 March, 2005 (29.03.05)

Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/000567

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JP 2002-514059 A1 (COR THERAPEUTICS INC.), 14 May, 2002 (14.05.02), & WO 1998/022583 A1 & EP 0939815 A1 & US 6194557 B1	1-19
A	WO 2002/012501 A2 (CENTOCOR INC.), 14 February, 2002 (14.02.02), & EP 1309693 A2 & JP 2004-510414 A1 & US 2004/0185507 A1	1-19
A	WO 2000/078815 A1 (APPLIED MOLECULAR EVOLUTION), 28 December, 2000 (28.12.00), & EP 1189946 A1 & JP 2004-537957 A1 & US 2003/0166872 A1	1-19

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/000567

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-7, 10-13 part of 16
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
(See extra sheet.)
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Continuation of Box No.II-2 of continuation of first sheet(2)

Claims 1 to 6 and 16

It is unknown that what specific substance "a substance or its derivative" according to claims 1 to 6 means. Thus, it appears that these claims are not clearly described.

Among "a substance or its derivative" as described above, nothing but the antibody #33, an anti-CD61 antibody and a fragmented (F(ab'2)) antibody #33 is indicated in practice as "being capable of binding to CD61 protein and having an effect of inhibiting the production of inflammatory cytokines" in EXAMPLES, etc. Namely, it is unknown what substances other than them correspond thereto. Moreover, an excessively large amount of trials and errors are needed for a person skilled in the art to confirm "being capable of binding to CD61 protein and having an effect of inhibiting the production of inflammatory cytokines" in practice. Therefore, the inventions according to the above claims are neither sufficiently supported by the description nor disclosed therein in a manner sufficiently clear and complete for the inventions to be carried out by a person skilled in the art.

No search was made on the inventions the claims of which are not clearly described and which are neither sufficiently supported by the description nor disclosed therein in a manner sufficiently clear and complete.

Claims 1 to 6 and 16

It is unknown that a substance of what specific structure "a derivative" according to the above claims means. Thus, it appears that these claims are not clearly described.

Although EXAMPLES and so on are examined concerning "a derivative" as described above, it is unknown what substances "are capable of binding to CD61 protein and have an effect of inhibiting the production of inflammatory cytokines". An excessively large amount of trials and errors are needed for a person skilled in the art to obtain such a substance. Therefore, the inventions according to the above claims are neither sufficiently supported by the description nor disclosed therein in a manner sufficiently clear and complete for the inventions to be carried out by a person skilled in the art.

No search was made on the inventions the claims of which are not clearly described and which are neither sufficiently supported by the description nor disclosed therein in a manner sufficiently clear and complete.

Claims 7 and 10 to 13

Concerning an anti-CD61 antibody encoded by "a DNA hybridizable under stringent conditions" and "a DNA encoding an amino acid sequence having deletion, addition, insertion and/or substitution of one or more amino acids" according to claim 7 and an anti-CD61 antibody having, as a heavy chain or a light chain, a polypeptide containing "an amino acid sequence having deletion, addition, insertion and/or substitution of one or more amino acids" according to claims 10 to 13, there is a low possibility that such a mutated anti-CD61 antibody has the same activity as the original antibody. Therefore, it is unknown a DNA or a polypeptide having what specific structure corresponds to the DNA or polypeptide according to the above claims. An excessively large amount of trials and errors are needed for a person skilled in the art to obtain such a DNA or polypeptide. Therefore, the inventions according to the above claims are neither sufficiently supported by the description nor disclosed therein in a manner sufficiently clear and complete for the inventions to be carried out by a person skilled in the art.

(Continued to the next sheet.)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/000567

Continuation of Box No.II-2 of continuation of first sheet (2)

No search was made on the inventions the claims of which are not clearly described and which are neither sufficiently supported by the description nor disclosed therein in a manner sufficiently clear and complete.